What Does Ongoing Monitoring for Tysabri-Related PML Involve?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding Drug Safety in Context

If you or a loved one is taking Tysabri and concerned about the risk of progressive multifocal leukoencephalopathy (PML), understanding the recommended follow-up monitoring can help you stay informed. The medical community has long emphasized the importance of structured surveillance for patients on immunomodulatory therapies, and this page outlines the key components of that clinical workup.

Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed this condition even without other immunosuppressive conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML compared to those who are antibody negative (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical trial data documented PML occurrence in patients receiving Tysabri. Two cases of PML were observed among 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). A third case occurred after eight doses in one of 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases demonstrate that PML can develop within the first year of treatment, as seen in the Crohn's disease patient, or after longer exposure, as seen in the multiple sclerosis patients.

Mechanism and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action on immune cell trafficking. Tysabri is an alpha-4 integrin antagonist that inhibits adhesion molecules on leukocytes, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for treating multiple sclerosis and Crohn's disease, but it also impairs normal immune surveillance. The JC virus, which is latent in many individuals, can reactivate and cause PML when immune monitoring of the brain is compromised. The presence of anti-JCV antibodies indicates prior exposure to the virus and is a marker for increased risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses (approximately 8 weeks) in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing experience has shown that risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri dosing immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Regulatory Warnings and Causation Considerations

The adequacy of warnings regarding Tysabri and PML is addressed through multiple regulatory mechanisms. The prescribing information includes a boxed warning that clearly states Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to inform patients and healthcare providers about the risk of PML and to ensure monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also specifies that Tysabri should not be used in combination with immunosuppressants or inhibitors of TNF-alpha in Crohn's disease patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For causation-related considerations, affected patients may need to establish that Tysabri use preceded the development of PML and that other potential causes, such as underlying immunosuppression, were not present. The known risk factors—anti-JCV antibodies, treatment duration, and prior immunosuppressant use—provide a framework for assessing individual risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical trial data showing PML in Tysabri-treated patients, including those receiving the drug as monotherapy or in combination with interferon beta-1a, supports a causal relationship (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, the evidence demonstrates that Tysabri causes an increased risk of PML, with specific risk factors and a documented timeline of harm. The drug's labeling includes prominent warnings and a restricted distribution program to mitigate this risk. Patients and healthcare providers must weigh the expected benefit of Tysabri against the risk of PML when considering treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Tysabri cause Progressive Multifocal Leukoencephalopathy?

Yes, Tysabri (natalizumab) increases the risk of PML, as stated in its boxed warning. Clinical trials and post-marketing data confirm a causal relationship, with risk factors including anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for PML in Tysabri-treated patients?

Three key risk factors are: presence of anti-JCV antibodies, treatment duration beyond two years, and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri increase the risk of PML?

Tysabri inhibits leukocyte migration across the blood-brain barrier, impairing immune surveillance. This allows reactivation of latent JC virus, leading to PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.